Setback for Pfizer drug Lyrica

Share this article:
In a setback for Pfizer, the FDA said it would classify its newly approved nerve pain drug Lyrica as a controlled substance.
Pfizer had been counting on Lyrica to offset declines in Neurontin, which saw patent expiration last year. But under the new controlled substance classification, Lyrica would be subject to the rules of the Drug Enforcement Agency and be more difficult to prescribe and dispense than generic Neurontin, known chemically as gabapentin.
Lyrica was approved to treat pain from nerves damaged by diabetes and shingles last week. The FDA is still reviewing the drug as an aid to managing epileptic seizures.
A Pfizer spokeswoman told The Wall Street Journal the launch date and price for Lyrica couldn't be determined until the DEA completes its review – a process that could take weeks or months. The spokeswoman declined to comment on what triggered the controlled substance classification.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.